PTC Therapeutics, Inc.
corporate_fare Company Profile
PTC Therapeutics, Inc. (NASDAQ:PTCT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for PTCT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-03, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for PTCT spans 10-Q, 8-K.
Recent high-impact activity:
- PTC Authorizes $500M Buyback With Stock Near 52-Week Low
- PTC 10-Q Details $2.13B Cash, $29.0M Nine-Month Profit After $111M ST-920 Charge
- PTC Q3 Revenue $358M, Full-Year Revenue Guidance Raised to $1.29-$1.32B
- PTC Therapeutics Posts $51.7M Q3 Loss
- PTC Therapeutics Strikes Asset Purchase Deal With Sangamo
Financial Snapshot
Short Interest & Short Volume
7.50 days to coverFINRA reported short interest of 7,779,250 shares in PTCT as of the October 30, 2026 settlement, a 6.3% decrease from the prior period — about 7.5 days to cover at its recent average daily volume. On November 20, 2026, 39.4% of PTCT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.